These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 19152406)
1. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463 [TBL] [Abstract][Full Text] [Related]
3. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249 [TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334 [TBL] [Abstract][Full Text] [Related]
5. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Zhang J; Lu Y; Dai J; Yao Z; Kitazawa R; Kitazawa S; Zhao X; Hall DE; Pienta KJ; Keller ET Prostate; 2004 Jun; 59(4):360-9. PubMed ID: 15065084 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388 [TBL] [Abstract][Full Text] [Related]
7. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764 [TBL] [Abstract][Full Text] [Related]
9. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239 [TBL] [Abstract][Full Text] [Related]
11. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Johnen H; Lin S; Kuffner T; Brown DA; Tsai VW; Bauskin AR; Wu L; Pankhurst G; Jiang L; Junankar S; Hunter M; Fairlie WD; Lee NJ; Enriquez RF; Baldock PA; Corey E; Apple FS; Murakami MM; Lin EJ; Wang C; During MJ; Sainsbury A; Herzog H; Breit SN Nat Med; 2007 Nov; 13(11):1333-40. PubMed ID: 17982462 [TBL] [Abstract][Full Text] [Related]
12. An in vivo model of prostate carcinoma growth and invasion in bone. Fisher JL; Schmitt JF; Howard ML; Mackie PS; Choong PF; Risbridger GP Cell Tissue Res; 2002 Mar; 307(3):337-45. PubMed ID: 11904770 [TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Dorai T; Dutcher JP; Dempster DW; Wiernik PH Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424 [TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326 [TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825 [TBL] [Abstract][Full Text] [Related]
18. Heparanase promotes bone destruction and invasiveness in prostate cancer. Zhou Y; Song B; Qin WJ; Zhang G; Zhang R; Luan Q; Pan TJ; Yang AG; Wang H Cancer Lett; 2008 Sep; 268(2):252-9. PubMed ID: 18487013 [TBL] [Abstract][Full Text] [Related]
19. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism. Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718 [TBL] [Abstract][Full Text] [Related]
20. [Mechanism of osteoblastic bone metastasis of prostate cancer]. Yonou H; Ogawa Y; Ochiai A Clin Calcium; 2006 Apr; 16(4):557- 64. PubMed ID: 16582505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]